Vera Therapeutics (VERA) EBITDA (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of EBITDA data on file, last reported at -$122.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 137.15% year-over-year to -$122.0 million; the trailing twelve-month figure through Mar 2026 stood at -$369.8 million (down 111.74% YoY), and the FY2025 full-year result was -$299.2 million, down 96.85% from the prior year.
• EBITDA for Q1 2026 stood at -$122.0 million, down from -$91.2 million in the prior quarter.
• Across five years, EBITDA topped out at -$15.0 million in Q2 2022 and bottomed at -$122.0 million in Q1 2026.
• The 5-year median for EBITDA is -$32.4 million (2022), against an average of -$44.6 million.
• The widest annual swing landed in 2022, when EBITDA sank 260.92%; it then grew 21.09% in 2023.
• A 5-year view of EBITDA shows it stood at -$32.4 million in 2022, then advanced by 21.09% to -$25.6 million in 2023, then slumped by 72.49% to -$44.1 million in 2024, then slumped by 106.9% to -$91.2 million in 2025, then plunged by 33.76% to -$122.0 million in 2026.
• The last three EBITDA figures came in at -$122.0 million (Q1 2026), -$91.2 million (Q4 2025), and -$79.9 million (Q3 2025), per Business Quant data.

Peer Comparison